CARs are sharpening their weapons
Open Access
- 31 January 2024
- journal article
- editorial
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (1) , e008275
Abstract
The tumor microenvironment hinders CAR T-cell access, activation, and persistence at the tumor site, thereby impacting on the therapeutic efficacy. To tackle these obstacles, ongoing efforts are focusing on further engineering CAR T-cells to enhance their homing, fitness, long-term persistence, and antitumor activity. Advances in genetic modification have prompted the development of armored CAR T-cells equipped with a combination of synergistic elements strengthening their function. These include cytokine release, chemokine receptor expression, immune checkpoint inhibition, gene-editing of inhibitory molecules, or metabolic reprogramming, among others. Multiarmored CAR T-cells may allow addressing the unmet clinical needs of patients with solid tumors or hard-to-treat hematological malignancies who do not benefit from conventional CAR T-cell therapy. Accordingly, several clinical trials are currently assessing the safety and efficacy of these novel CAR constructs.Keywords
Funding Information
- Ministero della Salute (PRIN 2021-NAZ-0033, RF-2021-12374120)
- AIRC (21147, 27507)
This publication has 24 references indexed in Scilit:
- Co‐expression of IL‐7 and PH20 promote anti‐GPC3 CAR‐T tumour suppressor activity in vivo and in vitroLiver International, 2020
- TRUCKS, the fourth‐generation CAR T cells: Current developments and clinical translationAdvances in Cell and Gene Therapy, 2020
- Interleukin-23 engineering improves CAR T cell function in solid tumorsNature Biotechnology, 2020
- Engineering strategies to overcome the current roadblocks in CAR T cell therapyNature Reviews Clinical Oncology, 2019
- Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid TumorsCancer Cell, 2019
- Teaching an old dog new tricks: next-generation CAR T cellsBritish Journal of Cancer, 2018
- Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer EradicationMolecular Therapy, 2018
- Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T CellsCancer Discovery, 2017
- Coexpressed Catalase Protects Chimeric Antigen Receptor–Redirected T Cells as well as Bystander Cells from Oxidative Stress–Induced Loss of Antitumor ActivityThe Journal of Immunology, 2016
- Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L ExpressionMolecular Therapy, 2015